The FDA wants to pull its approval of a drug. It’s not so easy.
The regulator says Tavneos was approved on the basis of manipulated study data. Should patients still have access to it?
This story comes from Ars Technica's feed; the full article and all rights belong to the source.
Comments (0)
No comments yet. Be the first to comment.
Sign in to write a comment.